Clearly, vinorelbine is an active agent which is well tolerated and suitable for use in the management of NSCLC. It is likely to play a greater role in the future.
The decade of the 1990s saw the introduction of several new agents with promising activity in advanced non-small cell lung cancer (NSCLC). Despite unequivocal evidence of activity and tolerability, the potential contribution of one of those drugs, vinorelbine, to the management of NSCLC has been relatively unappreciated.
Phase II trials in the elderly NSCLC patient suggested vinorelbine had promising activity with a manageable safety profile [1, 2] . The Italian phase III (ELVIS) study, reviewed in Tokyo by Cesare Gridelli [3], was conducted in elderly patients with advanced NSCLC and demonstrated that vinorelbine was superior to best supportive care in terms of survival as well as quality of life [4] .
Two other phase III trials, the seminal European trial led by Thierry Le Chevalier and reviewed by him in Tokyo [5] , as well as a U.S. trial conducted by the Southwest Oncology Group (SWOG), demonstrated that vinorelbine plus platinum was superior when compared either with one of the older platinum combinations, platinum as a single agent or vinorelbine alone [6, 7] . Follow-up of the European Organization for the Research and Treatment of Cancer (EORTC) study has now been extended to six years, with interesting data on long-term survivors and factors predictive of good prognosis.
Confirming and extending their initial results, the SWOG compared vinorelbine/cisplatin to carboplatin/paclitaxel and demonstrated equivalency in response rate and survival. The two regimens differed in their toxicity profiles, with carboplatin/paclitaxel surprisingly more neurotoxic and cisplatin/vinorelbine more emetogenic (largely due to the employment of high-dose cisplatin) [8] . An economic analysis found cisplatin/vinorelbine less expensive [9] . These trials are summarized in Table 1 .
In addition to an update and review of prior trials and regimens, the Tokyo meeting focused on the future role of vinorelbine. Two areas were discussed: further development of vinorelbine in combination chemotherapy of stage IV disease and the potential role in the multimodality management of stage III disease.
Given the emetogenecity of cisplatin, it is logical to substitute carboplatin and evaluate carboplatin/vinorelbine in stage IV patients. Gregory Masters discussed the potential benefit of substituting carboplatin for cisplatin in combination with vinorelbine [10] . In a phase I/II study in which the two drugs were given on days 1 and 8 every three weeks, little significant hematologic and nonhematologic toxicity was observed [11] . Recent studies have demonstrated that 2 New Directions in the Treatment of Non-Small Cell Lung Cancer platinums are no longer essential for the treatment of advanced disease, with nonplatinum regimens achieving similar results in terms of response and survival. Rogerio Lilenbaum reported on a phase II trial of vinorelbine/gemcitabine [12, 13] . The response rate of 25%, median eight-month survival and 38% rate of one-year survival are comparable to those seen with the platinum-based combinations employed in Eastern Cooperative Oncology Group 1594 (Table 1) , and were achieved with little nonhematologic toxicity [12, 14] .
Chemotherapy plays an essential role in the management of locally advanced (i.e., stage III) disease with the weight of evidence supporting improved curability of this stage when drugs are employed either preoperatively or as part of a chemoradiotherapy regimen. Mark Socinski reported that induction therapy using carboplatin/vinorelbine or carboplatin/paclitaxel can be followed by accelerated conformal radiation therapy without causing undue toxicity [15] . The rate of response to induction chemotherapy is promising and preliminary analysis suggests the one-year survival rate will be 65%.
Everett Vokes updated the randomized phase II trial conducted by the Cancer and Leukemia Group B in stage III patients receiving multimodality treatment. The arm utilizing cisplatin/vinorelbine was less toxic than the comparator agents (particularly with respect to esophagitis) while being at least as active [16, 17] .
Not discussed at the meeting, but of great interest, is the potential role of vinorelbine in adjuvant therapy. Depending upon stage, between 25%-70% of patients with stage I-IIb who undergo potentially curative resection will ultimately relapse. Despite hints from meta-analysis that adjuvant platinum-based therapy may be beneficial [18] , currently available data do not support adjuvant treatment [19] . The NCI-Canada study (JBR-10) of cisplatin/vinorelbine versus no therapy is currently accruing patients and will be the first study to test a "modern" chemotherapy regimen in this setting.
Clearly, vinorelbine is an active agent which is well tolerated and suitable for use in the management of NSCLC. It is likely to play a greater role in the future. 
